Hoxton Planning & Management LLC lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,375 shares of the company’s stock after selling 112 shares during the quarter. Hoxton Planning & Management LLC’s holdings in AbbVie were worth $213,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of ABBV. Retirement Income Solutions Inc bought a new position in AbbVie during the 1st quarter valued at about $204,000. Ergoteles LLC grew its holdings in AbbVie by 17.8% during the 1st quarter. Ergoteles LLC now owns 5,605 shares of the company’s stock valued at $909,000 after purchasing an additional 847 shares during the last quarter. First Western Trust Bank bought a new position in AbbVie during the 1st quarter valued at about $1,150,000. Wsfs Capital Management LLC bought a new position in AbbVie during the 1st quarter valued at about $562,000. Finally, Bridgewater Associates LP grew its holdings in AbbVie by 80.4% during the 1st quarter. Bridgewater Associates LP now owns 75,516 shares of the company’s stock valued at $12,242,000 after purchasing an additional 33,661 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Stock Down 0.4 %
ABBV stock opened at $161.67 on Tuesday. The firm has a market cap of $286.26 billion, a PE ratio of 59.22, a P/E/G ratio of 2.07 and a beta of 0.58. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. The firm’s fifty day moving average is $176.23 and its 200 day moving average is $159.81. AbbVie Inc. has a one year low of $130.96 and a one year high of $182.89.
AbbVie Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $1.55 per share. This represents a $6.20 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Friday, April 12th. AbbVie’s payout ratio is 227.11%.
Insider Buying and Selling at AbbVie
In other AbbVie news, SVP Kevin K. Buckbee sold 5,144 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $176.65, for a total transaction of $908,687.60. Following the transaction, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,233,546.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the transaction, the executive vice president now directly owns 243,944 shares of the company’s stock, valued at $42,375,512.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Kevin K. Buckbee sold 5,144 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $176.65, for a total transaction of $908,687.60. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,233,546.95. The disclosure for this sale can be found here. Insiders have sold a total of 383,324 shares of company stock valued at $67,780,003 over the last ninety days. Corporate insiders own 0.25% of the company’s stock.
Wall Street Analyst Weigh In
ABBV has been the topic of a number of research analyst reports. Barclays upped their target price on shares of AbbVie from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 27th. Raymond James upped their price target on shares of AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Guggenheim upped their price target on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. William Blair raised shares of AbbVie from a “market perform” rating to an “outperform” rating in a research report on Monday, January 29th. Finally, HSBC cut shares of AbbVie from a “buy” rating to a “hold” rating and lowered their price target for the stock from $167.00 to $156.00 in a research report on Monday, December 18th. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $177.43.
Read Our Latest Research Report on AbbVie
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
- Five stocks we like better than AbbVie
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- What is the Nasdaq? Complete Overview with History
- Bank Stocks – Best Bank Stocks to Invest In
- What is a Secular Bull Market?, How to Identify this Market
- Investing in the High PE Growth Stocks
- Star Surgical Shines as U.S. Outlook Improves for 2024
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.